A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for monocarboxylate transporters as metabolic targets for therapy

Journal of Pathology

Volumn 236, Issue 4, 2015, Pages 517-530

  Pertega Gomes, Nelma ^a   Felisbino, Sergio ^b   Massie, Charlie E ^a   Vizcaino, Jose R ^c   Coelho, Ricardo ^d   Sandi, Chiranjeevi ^a   Simoes Sousa, Susana ^e,f   Jurmeister, Sarah ^a   Ramos Montoya, Antonio ^a   Asim, Mohammad ^a   Tran, Maxine ^a   Oliveira, Elsa ^d   Lobo Da Cunha, Alexandre ^d   Maximo, Valdemar ^d,g   Baltazar, Fatima ^e,f   Neal, David E ^a,h   Fryer, Lee G D ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c Centro Hospitalar Universitario do Porto   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF MINHO   (Portugal)

^f UNIVERSITY OF MINHO   (Portugal)

^g University of Porto   (Portugal)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cell metabolism; metabolic targets; monocarboxylate transporters; poor prognosis markers; prostate cancer

Indexed keywords

CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCARBOXYLATE TRANSPORTER;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER MODEL; DISEASE ASSOCIATION; DISEASE COURSE; EX VIVO STUDY; GENETIC TRANSFECTION; GLUCOSE INTAKE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DRUG DESIGN; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TIME; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; LACTIC ACID; MALE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASM STAGING; PHENOTYPE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84937469514     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4547     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Gatenby RA, Gillies RJ,: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-899.
3. Cairns RA, Harris IS, Mak TW,. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
4. Vander Heiden MG,: Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671-684.
5. Hamanaka RB, Chandel NS,: Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209: 211-215.
6. 18fluorine-labeled deoxyglucose. J Urol 1996; 155: 994-998.
7. 18 F] fluorodeoxyglucose in untreated prostate cancer. Japan J Clin Oncol 1999; 29: 623-629.
8. Ertel A, Tsirigos A, Whitaker-Menezes D, et al., Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle 2012; 11: 253-263.
9. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
10. Dakubo GD, Parr RL, Costello LC, et al., Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006; 59: 10-16.
11. Costello LC, Franklin RB, Feng P,. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 143-153.
12. Benedettini E, Nguyen P, Loda M,. The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol 2008; 14: 195-201.
13. Pertega-Gomes N, Vizcaino JR, Gouveia C, et al., Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate 2013; 73: 763-769.
14. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, et al., Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011; 11: 312.
15. Pertega-Gomes N, Vizcaino JR, Attig J, et al., A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer 2014; 14: 352.
16. Hao J, Chen H, Madigan MC, et al., Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 2010; 103: 1008-1018.
17. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, et al., Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44: 127-139.
18. Baltazar F, Pinheiro C, Morais-Santos F, et al., Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol 2014; 29: 1511-1524.
19. Miranda-Goncalves V, Honavar M, Pinheiro C, et al., Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro-oncology 2013; 15: 172-188.
20. Ganapathy-Kanniappan S, Kunjithapatham R, Geschwind JF,. Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting. Anticancer Res 2013; 33: 13-20.
21. Sonveaux P, Vegran F, Schroeder T, et al., Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118: 3930-3942.
22. Sonveaux P, Copetti T, De Saedeleer CJ, et al., Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PloS One 2012; 7: e33418.
23. Kim HS, Masko EM, Poulton SL, et al., Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int 2012; 110: 1062-1069.
24. Glinsky GV, Glinskii AB, Stephenson AJ, et al., Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113: 913-923.
25. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al., Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9: 166-180.
26. Varambally S, Yu J, Laxman B, et al., Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.
27. Grasso CS, Wu YM, Robinson DR, et al., The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
28. Massie CE, Lynch A, Ramos-Montoya A, et al., The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011; 30: 2719-2733.
29. Porporato PE, Dhup S, Dadhich RK, et al., Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2: 49.
30. Dhup S, Dadhich RK, Porporato PE, et al., Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharmaceut Design 2012; 18: 1319-1330.
31. Guile SD, Bantick JR, Cheshire DR, et al., Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds. Bioorg Med Chem Lett 2006; 16: 2260-2265.
32. Bakin RE, Gioeli D, Sikes RA, et al., Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63: 1981-1989.
33. Park SY, Kim YJ, Gao AC, et al., Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006; 66: 5121-5129.
34. Deitmer JW, Becker HM,. Transport metabolons with carbonic anhydrases. Front Physiol 2013; 4: 291.
35. Zhou Z, Flesken-Nikitin A, Nikitin AY,. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 2007; 67: 5683-5690.
36. + symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA 2011; 108: 16663-16668.
37. + symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin. Cancer Res 2015; 75: 171-180.
38. Doherty JR, Yang C, Scott KE, et al., Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res 2014; 74: 908-920.